Summary
GlobalData, the industry analysis specialist's new report, "Macular Oedema-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global macular oedema market. The report identifies the key trends shaping and driving the global macular oedema market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global macular oedema sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
=Annualized global macular oedema market revenues data from 2000 to 2009, forecast forward for 7 years to 2016.
=Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
=Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
=Analysis of the current and future market competition in the global macular oedema market.
=Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
=Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with macular oedema. Key market players discussed include pSivida Corp, Genentech, Pfizer, Bausch and Lomb, and i-Co Therapeutics.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
=Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
=Develop business strategies by understanding the trends shaping and driving the global macular oedema market.
=Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global macular oedema market in future.
=Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
=Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
=Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
=What's the next big thing in the global macular oedema market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Macular Oedema Market: Market Characterization 5
2.1 Overview 5
2.2 Macular Oedema Market Size 5
2.3 Macular Oedema Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Macular Oedema Market 7
2.4.1 Drivers of the Macular Oedema Market 7
2.4.2 Barriers for the Macular Oedema Market 8
3 Opportunity and Unmet Need 9
3.1 Key Takeaway 10
4 Macular Oedema Market: Competitive Assessment 11
4.1 Overview 11
4.2 Strategic Competitor Assessment 11
4.3 Product Profile for the Major Marketed Products in the Macular Oedema Market 11
4.3.1 Kenalog 11
4.3.2 Avastin (Genentech) 13
4.3.3 Lucentis (Genentech) 14
4.3.4 Ozurdex (Allergan) 15
4.4 Key Takeaway 16
5 Macular Oedema Market: Pipeline Assessment 17
5.1 Overview 17
5.2 Strategic Pipeline Assessment 17
5.2.1 Technology Trends Analytic Framework 17
5.3 Macular Oedema Therapeutics-Promising Drugs under Clinical Development 19
5.4 Drugs Profile under Clinical Development 20
5.4.1 Iluvien 20
5.4.2 iCo-007 20
5.5 Macular Oedema Therapeutics Market-Clinical Pipeline by Mechanism of Action 21
5.6 Macular Oedema Pipeline-Pipeline by Clinical Phases of Development 22
5.6.1 Macular Oedema Therapeutics-Phase III Clinical Pipeline 23
5.6.2 Macular Oedema Therapeutics-Phase II Clinical Pipeline 23
5.6.3 Macular Oedema Therapeutics-Phase I Clinical Pipeline 24
5.6.4 Macular Oedema Therapeutics-Preclinical Pipeline 24
5.7 Discontinued/Suspended Drugs for Macular Oedema 24
5.8 Key Takeaway 25
6 Macular Oedema Market: Implications for Future Market Competition 26
7 Macular Oedema Market: Future Players in the Macular Oedema Market 27
7.1 Introduction 27
7.2 pSivida Corp 27
7.2.1 Overview 27
7.2.2 Business Description 27
7.2.3 Ophthalmology Portfolio 28
7.2.4 Macular Oedema Product Portfolio 28
7.3 Genentech. 29
7.3.1 Overview 29
7.3.2 Business Description 29
7.3.3 Ophthalmology Portfolio 30
7.3.4 Macular Oedema Product Portfolio 30
7.4 I co Therapeutics 31
7.4.1 Overview 31
7.4.2 Ophthalmology Portfolio 31
7.4.3 Macular Oedema Product Portfolio 31
7.5 Pfizer 32
7.5.1 Company Overview 32
7.5.2 Business Description 32
7.5.3 Ophthalmology Portfolio 33
7.5.4 Macular Oedema Product Portfolio 33
8 Macular Oedema Market: Appendix 35
8.1 Definitions 35
8.2 Research Methodology 35
8.2.1 Coverage 36
8.2.2 Secondary Research 36
8.2.3 Forecasting 37
8.2.4 Primary Research 39
8.2.5 Expert Panels 40
8.3 Contact Us 40
8.4 Disclaimer 40
8.5 Sources 41

List of Tables
1.1 List of Tables
Table 1: Global  Macular Oedema Market, Revenue ($bn), 2001-2009 6
Table 2: Global Macular Oedema Market, Revenue ($bn), 2009-2016 7
Table 3: Strategic Competitor Assessment of the Major Marketed Products in Macular Oedema, 2010 11
Table 4: Clinical Trial Results for Lucentis in Macular Oedema Patients. 14
Table 5: Major Marketed Product in the Macular Oedema Market, 2010 16
Table 6: Macular Oedema Therapeutics-Promising Drugs Under Clinical Development, 2010 19
Table 7: Macular Oedema Therapeutics-Phase III Clinical Pipeline, 2010 23
Table 8: Macular Oedema Therapeutics-Phase II Clinical Pipeline, 2009 23
Table 9: Macular Oedema Therapeutics-Phase I Clinical Pipeline, 2010 24
Table 10: Macular Oedema Therapeutics-Preclinical Pipeline, 2010 24
Table 11: List of Discontinued Drugs for Macular Oedema, 2010 24
Table 12: pSivida Corp-Ophthalmological Marketed Products, 2010 28
Table 13: pSivida Corp-Ophthalmological Pipeline Products, 2010 28
Table 14: Genentech-Macular Oedema Marketed Products, 2010 30
Table 15: Genentech-Macular Oedema Pipeline Products, 2010 30
Table 16: Clinical Trial Results for Lucentis in Macular Oedema Patients. 31
Table 17: I co Therapeutics-Macular Oedema Pipeline Products, 2010 31
Table 18: Pfizer-Macular Oedema Marketed Products, 2010 33
Table 19: Pfizer-Macular Oedema Pipeline Products, 2010 33

List of Figures
1.2 List of Figures
Figure 1: Global Macular Oedema Market, Revenue ($bn), 2001-2009 6
Figure 2: Global Macular Oedema Market, Revenue ($bn), 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Macular Oedema Market, 2010 9
Figure 4: Technology Trends Analytic Framework of the Macular Oedema Pipeline, 2010 17
Figure 5: Technology Trends Analytic Framework  of Macular Oedema Pipeline-Description, 2010 18
Figure 6: Macular Oedema Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 22
Figure 7: Macular Oedema Pipeline by Phase of Clinical Development, 2010 22
Figure 8: Implications for Future Market Competition in the Macular Oedema Market, 2010 26
Figure 9: Macular Oedema Therapeutics Market-Clinical Pipeline by Company, 2010 27
Figure 10: GlobalData Methodology 36
Figure 11: GlobalData Market Forecasting Model 39